Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBT: 2015-2024

Historic EBT for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$124.0 million.

  • UroGen Pharma's EBT fell 45.88% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.6 million, marking a year-over-year decrease of 45.18%. This contributed to the annual value of -$124.0 million for FY2024, which is 26.16% down from last year.
  • Per UroGen Pharma's latest filing, its EBT stood at -$124.0 million for FY2024, which was down 26.16% from -$98.3 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's EBT ranged from a high of -$98.3 million in FY2023 and a low of -$125.1 million during FY2020.
  • Its 3-year average for EBT is -$110.1 million, with a median of -$108.0 million in 2022.
  • As far as peak fluctuations go, UroGen Pharma's EBT climbed by 12.58% in 2021, and later fell by 26.16% in 2024.
  • UroGen Pharma's EBT (Yearly) stood at -$125.1 million in 2020, then increased by 12.58% to -$109.4 million in 2021, then rose by 1.23% to -$108.0 million in 2022, then climbed by 8.98% to -$98.3 million in 2023, then declined by 26.16% to -$124.0 million in 2024.